Renovacare, Inc. · OTC:RCAR
Renovacare — Investor Presentation (November 2020)
27 slides from Renovacare's investor presentation, Nov 3, 2020
Slide 1: SkinGun & CellMist Next Generation Ultra-Gentle Cell Spray
SkinGun Œ & CellMist Œ Next Generation Ultra - Gentle Cell Spray S y m b o l : RC A R RenovaCare Investor Forum 1 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved. October 29, 2020
Slide 2: Forward-looking statements
This slide deck and the accompanying oral presentation contain forward - looking statements, including, but not limited to, statements related to RenovaCare Inc . ’s future financial and operating results, including 2019 financial guidance, 2020 goals and expectations for growth ; the company’s corp
Slide 3: Today's Presenters
Alan L. Rubino Chairman & CEO Robin A. Robinson, PhD Chief Scientific Officer Robert W. Cook Chief Financial Officer Today’s Presenters 3 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved. October 29, 2020
Slide 4: RenovaCare: Past, Present and Future
Development at StemCell Systems: SkinGun ΠCell Spray Device CellMist ΠCell Isolation Process Historical: Discovery Current: Clinical Future: Commercial Co m pa n y Focus T e c hn o l o g y Evolution Electronic SkinGun ΠDisposable SkinGun ΠCellMist ΠSystem Closed Cell Isolation Device Advanced R
Slide 5: Focused Strategies to Meet Long-Term Objectives
DIVERSE PRODUCT PORTFOLIO Burns, chronic wounds, acute wounds and scars ; regeneration of skin and other organs and tissues DISCIPLINED CAPITAL ALLOCATION Ba l a n c e d t o s u pp o r t p o r t f o li o g r o w t h opportunities, financings, corporate development and shareholder returns ROBUST, EXP
Slide 6: Next-Generation Biomedical Technologies Devices & Products
Next - Generation Biomedical Technologies Devices & Products 6 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 7: New Treatment for Wounds is Urgently Needed
Patented technologies for isolating and spraying self - donated stem cells for the regeneration of skin and other organs and tissues. RenovaCare autologous cellular therapies are used to treat burns, scars, skin disorders, wounds, and cosmetic applications. An estimated $25 billion is spent annually
Slide 8: Grafting is Painful, Expensive and Leaves Scarring
Grafting is Painful, Expensive and Leaves Scarring Skin Grafting is Current Standard - of - Care Painful & Lengthy Treatment Cycle › 200 - year old method with the last breakthrough 50 years ago › Large sheets of skin are surgically removed and re - stitched onto wound › Painful procedure that leave
Slide 9: RenovaCare SkinGun Technology
RenovaCare SkinGun Œ Technology *Treated under special innovative practice approach at: Berlin - Brandenburg Center for Regenerative Therapies, Charité Berlin; and under innovative practice approach at UPMC Medical Center, Pittsburgh, Pennsylvania. **Raw patient data available. 70+ Patients Su c c e
Slide 10: RenovaCare Breakthrough Technology
RenovaCare Breakthrough Technology CellMist Œ uses donor tissue sample. RenovaCare CellMist Œ Split Thickness Skin Graft 10cm 2 donor sample Donor Skin Sample 10cm 2 Typical › Small donor skin sample taken under local anesthetic › 90 minutes to harvest regenerative autologous stem cells › Water - ba
Slide 11: Our Execution Will Lead To Four Major Submissions for Approval
IDE/PMA 510(k) 510(k) 510(k) CellMist System ΠElectronic SkinGun ΠAutologous Skin Stem Cell Therapy for Burns POTENTIAL APPROVALS FROM 2020 - 2025 Disposable SkinGun ΠCell Spray Deposition Device Electronic SkinGun ΠCell Spray Deposition Device Cell Isolation Device Multi - Tissue Automated Clos
Slide 12: Building A Pipeline For Sustainable Growth
Building A Pipeline For Sustainable Growth TARGETED APPROVALS WITHIN 5 YEARS: ONE BURN PMA + TWO SKINGUN Œ 510(k) 12 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 13: The RenovaCare Electronic SkinGun
The RenovaCare Electronic SkinGun ΠOUR PATENTED CELL SPRAY TECHNOLOGIES SPRAY - ON STEM CELLS FOR RAPID HEALING Controlled Spray Large - Area Coverage Ultra - Gentle Deposition Ultra - Precise Even Distribution Even Droplets No Droplet Loss Non - Drip No Roll - Off Actual SkinGun ΠSpray 13 RenovaC
Slide 14: Research. Development. Innovation.
Research. D e v e l o p m e n t . Innovation. 14 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 15: RenovaCare R&D and Innovation Team
Bioengineering & Cell Biology Regenerative Medicine Medical Device Engineering and Prototyping Regulatory - Centric IP Driven Engineering QMS Support Documentation RenovaCare R&D and Innovation Team 2 MD - PhDs 2 PhDs 1 MBA - Engineer 4 Engineers RenovaCare R&D Innovation Center SURGERY BIOENGINEERI
Slide 16: RenovaCare IP Summary
RenovaCare IP Summary 16 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 17: Expanding Our Intellectual Property
2011 2013 2016 2018 2019 Cell spray device developed Di s p o s a b l e SkinGun ΠEncompass all types of cell tissues or organs Modular handheld spray device to spray cells Additional RenovaCare IP filings Electronic S k i n G un ΠIP tested and validated 2020 Cell isolation process developed Expand
Slide 18: Disciplined Pathway & World Class Management
Disciplined Pathway & World Class Management 18 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 19: Commercial Market Potential
$1B ~ $ 60 0 - 700M ~ $ 200 - 300M ~$2B in - patient burns severe second degree operation theater RenovaCare Regenerative Cell Therapies POTENTIAL TWO BILLION DOLLAR MARKET OPPORTUNITY WITHIN THE U.S. Advanced Burn Care Current Market out - patient burns pediatric scalds clinical setting wounds trau
Slide 20: Partners Enabling Clinical Pathway
R&D / QMS Cl i n i c al Manufacturing Regulatory Partners Enabling Clinical Pathway DATA - DRIVEN PARTNERS WITH AN UNWAVERING FOCUS ON IMPACT 20 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 21: 2020 Milestones / Goals
Regulatory Priorities Planned Clinical Trials Corporate Development Activities Five Sites Selected: Q1 2020 FDA IDE Submission: Q3 2020 FDA 510(k) Submission: 1H 2021 Hiring strategic talent to drive corporate activities, clinical trials, and FDA submissions Expand portfolio through multiple collabo
Slide 22: Experienced Leadership Team
COMMERCIALIZATION OPERATIONS REGULATORY R & D MANUFACTURING CLINICAL FU L L Y - I N T EG R A T ED CAPABILITIES Alan L. Rubino CEO / President / Chairman Robert Cook Chief Financial Officer Dr. Robin Robinson Chief Scientific Officer Dr. Jo Schweinle Chief Medical Officer Joseph Sierchio General Coun
Slide 23: Building For Success Focused On Results
Building For Success Focused On Results 23 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 24: Financial Highlights
~$320 Million Market Cap Closing price at 23 - Oct - 2020: $3.68 $10.2 Million Cash - on - Hand $14.3 Million Stockholders Equity Financials as of June 30, 2020 RenovaCare, Inc. Symbol: RCAR $1.9 Million Cash Used In Operations – 6 months ~87 Million Outstanding Shares ~18.1 Million Outstanding Warr
Slide 25: Building Shareholder Value
Building Shareholder Value RenovaCare: Focused, Growing, Disciplined & Proven 1. Focused Portfolio: Cutting - Edge Stem - Cell Spray Therapies ▪ cell isolation and spray technologies ▪ stem cell therapies for acute and chronic wounds, including burns ▪ highly - innovative, proven R&D group (IP, regu
Slide 26: Questions & Answers
Questions & Answers 26 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved.
Slide 27: Thank you for your participation
spray - on stem cells for rapid healing . 27 RenovaCare Investor Forum I October 2020 © 2020 RenovaCare Inc. All rights reserved. SkinGun Œ & CellMist Œ Next Generation Ultra - Gentle Cell Spray Symbol: RCAR Thank you for your participation. October 29, 2020 RenovaCare, Inc. contact@renovacareinc.co